在鼻癌中通过抑制PD-L1表达来抑制BRD7抑制免疫逃逸
Yilin Guo1,2,3, Jiaxue Lu1,3, Xiaoxu Li4
1Department of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
International journal of biological sciences
|March 14, 2025
概括
瘤抑制基因BRD7通过降低PD-L1表达的调节来抑制鼻癌 (NPC) 免疫逃脱. 将BRD7与PD-L1抗体治疗结合起来可以增强抗瘤效果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 利用抗瘤免疫力是一个关键的癌症治疗策略.
- PD-1/PD-L1通路对于恢复抗瘤免疫反应至关重要.
- 确定了BRD7,这是鼻癌 (NPC) 中的一种瘤抑制基因.
研究的目的:
- 研究BRD7在NPC预后中的作用及其对PD-L1表达的调节.
- 阐明BRD7影响瘤免疫微环境的机制.
- 评估BRD7与PD-L1阻断结合的治疗潜力.
主要方法:
- 评估了BRD7与NPC患者预后的关联.
- 研究了BRD7对NPC细胞中PD-L1表达和CD8+T细胞活性的影响.
- 使用体内模型来评估BRD7和PD-L1抗体组合疗法.
主要成果:
- BRD7表达与更好的NPC患者预后相关.
- 通过抑制PI3K/AKT/mTOR/STAT3通路,BRD7降低了PD-L1的表达.
- BRD7 增强了 CD8+ T 细胞杀死功能,并抑制了瘤的生长.
- 结合BRD7和PD-L1抗体疗法显示抗瘤疗效得到改善.
结论:
- BRD7通过抑制免疫逃逸,在NPC中起到瘤抑制作用.
- BRD7降低了PD-L1的调节,增强了抗瘤免疫力.
- BRD7代表了NPC的潜在治疗点,特别是在组合策略中.
更多相关视频
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
196
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.1K
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
